SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that thymalfasin, the chemical composition of ZADAXIN®, has been granted Orphan Drug designation for the treatment of stage IIb through stage IV malignant melanoma by the U.S. Food and Drug Administration (FDA). Orphan Drug designation could provide SciClone with seven years of market exclusivity in the United States should ZADAXIN receive regulatory approval from the FDA for the treatment of malignant melanoma.
